comparemela.com

Latest Breaking News On - Good clinical - Page 13 : comparemela.com

Börse Express - CATO SMS ernennt Leiter für Regulierungsstrategie

Börse Express - CATO SMS ernennt Leiter für Regulierungsstrategie
boerse-express.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-express.com Daily Mail and Mail on Sunday newspapers.

CATO SMS ernennt Leiter für Regulierungsstrategie

CATO SMS ernennt Leiter für Regulierungsstrategie
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Regulatory Administrator (FTC) Wits RHI

Jun 4, 2021 A Regulatory Administrator (Fixed Term Contract) vacancy is available at our Client, Wits Health Consortiums Wits Reproductive Health and HIV Institute (Wits RHI) in Hillbrow, Johannesburg – Gauteng. Background The Wits Reproductive Health and HIV Institute (Wits RHI) is a renowned African-led research institute that seeks solutions to Africas health challenges. It is located within the University of the Witwatersrand and addresses some of the greatest public health concerns affecting our region, including HIV and its related problems, sexual and reproductive health, and vaccinology. This is done through pioneering, multi-disciplinary research; responsive technical support and innovation in health services; and evidence-based policy development and advocacy with national, regional, and global stakeholders.

Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain QIXLEEF has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 11, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the acceleration of a revolutionary Phase 2 clinical trial, PLENITUDE©, to evaluate the safety and efficacy of the investigational cannabis medicine, QIXLEEF, for use in managing uncontrolled pain in patients with advanced cancer. QIXLEEF is the Company s inhaled proprietary drug formulation which has a fixed ratio of THC and CBD. The medication is inhaled through a Class II medical vaporizer. When pharmaceutical grade cannabis is vaporized rather than smoked, the beneficial components can be inhaled without the generation of smoke and combusted by-products.

L ANSM valide par précaution le retrait de la vente de 9 médicaments

L ANSM valide par précaution le retrait de la vente de 9 médicaments
sixactualites.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sixactualites.fr Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.